Hepatitis C Virus Quasi-Species Dynamics Predict Progression of Fibrosis after Liver Transplantation
Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib A, Fasola C, Adair D, Radkowski M, Kibler KV, Nowicki M, Douglas D, Williams J, Netto G, Mulligan D, Klintmalm G, Rakela J, Vargas HE. Hepatitis C Virus Quasi-Species Dynamics Predict Progression of Fibrosis after Liver Transplantation. The Journal Of Infectious Diseases 2004, 189: 2037-2046. PMID: 15143471, DOI: 10.1086/386338.Peer-Reviewed Original ResearchMeSH Keywords5' Untranslated RegionsDisease ProgressionElectrophoresis, Polyacrylamide GelFemaleGenetic VariationHepacivirusHepatitis C, ChronicHumansLiver CirrhosisLiver TransplantationMaleMiddle AgedPhylogenyPolymorphism, Single-Stranded ConformationalReverse Transcriptase Polymerase Chain ReactionRNA, ViralViral Envelope ProteinsConceptsOrthotopic liver transplantationHepatitis C virusLiver transplantationGroup 1Quasi speciesSeverity of recurrenceGroup 1 patientsGroup 2 patientsE2 regionProgression of fibrosisPost-OLT periodCourse of infectionHeteroduplex mobility assayHCV complexityHCV infectionC virusGroup 2PatientsTransplantationSingle-strand conformational polymorphismLiver samplesInfectionWeeksQuasi-species dynamicsYearsTreatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1. Transplantation 2004, 77: 190-194. PMID: 14742979, DOI: 10.1097/01.tp.0000100481.14514.bb.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunosuppressive AgentsInterferon alpha-2Interferon-alphaLiver Function TestsLiver TransplantationMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRecurrenceReverse Transcriptase Polymerase Chain ReactionRibavirinRNA, ViralTime FactorsTreatment OutcomeConceptsOrthotopic liver transplantationEnd of treatmentHCV recurrenceLiver transplantationPEG-IFNHepatitis C virus recurrenceRecurrent hepatitis C infectionDiscontinuation of therapyNecro-inflammatory scoreUndetectable viral loadHepatitis C infectionResponse 6 monthsBone marrow toxicityReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHistologic benefitRecurrent HCVVirologic clearanceC infectionVirologic responseVirus recurrenceAggressive managementCombination regimenViral clearanceViral response